drugset / Trial / NCT06207734
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
Phase 2
Recruiting
120 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
Timeline
- Start
- 2024-01-17
- Primary completion
- 2027-01-10
- Completion
- 2028-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abemaciclib | Small molecule | — | — |
| Comparator | Palbociclib | Small molecule | — | — |